Updated interim results from the German “Mogamulizumab In a Non-interventional study to evaluate the safety and outcome in mycosis fungoides and Sézary syndrome Treatment” (MINT) study

IF 7.1 1区医学 Q1 ONCOLOGY

European Journal of Cancer Pub Date : 2025-10-01 DOI:10.1016/j.ejca.2025.115891

Chalid Assaf, Gabor Dobos, Max Schlaak, Nina Booken, Mathias Oymanns, Kai-Christian Klespe, Jan Nicolay, Marion Wobser, Lennart Ocker, Sebastian Haferkamp, Patrick Terheyden, Carsten Weishaupt, Christian Menzer, Claus-Detlev Klemke, Johannes Wohlrab, Marlene Garzarolli, Oana-Diana Persa, Ulrich Wehry, Edgar Dippel, Andreas Bachinger, Azeem Danish

引用次数: 0

查看原文本刊更多论文

德国“Mogamulizumab在非介入研究中评估蕈样真菌病和ssamzary综合征治疗的安全性和结果”（MINT）研究的最新中期结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

European Journal of Cancer 医学-肿瘤学

CiteScore

11.50

自引率

4.80%

发文量

953

审稿时长

23 days

期刊介绍： The European Journal of Cancer (EJC) serves as a comprehensive platform integrating preclinical, digital, translational, and clinical research across the spectrum of cancer. From epidemiology, carcinogenesis, and biology to groundbreaking innovations in cancer treatment and patient care, the journal covers a wide array of topics. We publish original research, reviews, previews, editorial comments, and correspondence, fostering dialogue and advancement in the fight against cancer. Join us in our mission to drive progress and improve outcomes in cancer research and patient care.